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INTRODUCTION
The annual volume of coronary revascularization in Korea is 
continuously increasing since 2006, although this trend differs 
according to procedure type. A high percentage of drug-eluting 
stent (DES) procedures are noted.1
DES with a polymer surface and a controlled release of anti-
proliferative agents represent a breakthrough in stent manu-
facturing technology. This has reduced the incidence of reste-
nosis and the need for revascularization compared with bare-
metal stents (BMS).2-4 However, concerns have emerged 
regarding late and very late stent thrombosis with first genera-
tion DES that in turn are associated with a high rate of death 
and myocardial infarction (MI).5,6 The remaining polymer ma-
terial after the complete release of the drug coating is a poten-
tial hazard for inflammatory reactions that end up with incom-
plete endothelialization of stent struts and positive remodeling, 
hence, stent thrombosis and MI.7,8
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In order to overcome this issue, new devices have been de-
veloped; the second generation DES with new metal alloys and 
durable polymers (biocompatible polymer) to lower the risk of 
inflammation or biodegradable polymers combined with stain-
less steel platforms that are absorbed leaving the stent surfaces 
similar to that of BMS. Different types of durable polymer DES 
have been extensively studied in randomized clinical trials, 
however, few studies so far have compared durable vs. biode-
gradable polymer stents.9,10
We herein compared a durable polymer Zotarolimus-eluting 
stent (ZES) with a biodegradable polymer Biolimus-eluting 
stent (BES).
MATERIALS AND METHODS
Study population and design
The CONSTANT registry was a prospective, open labeled, multi-
center registry including single center randomized study. It in-
cluded patients undergoing single lesion per single vessel per-
cutaneous coronary intervention (PCI) with Resolute integrity 
DES. The NOBORI registry, on the other hand, is an open label, 
multi-center observational registry that also included patients 
undergoing PCI with Biolimus A9-eluting stent (Nobori DES) 
for all-comer patients per single coronary lesion. Patient’s en-
rollment was all-comer diagnosed as stable angina and acute 
coronary syndrome who are indicated for coronary revascu-
larization as targeted lesion which was significant (>70% by 
quantitative angiographic analysis) and a single lesion per sin-
gle vessel, confirmed by stress test, imaging study or cardiac 
enzymes.
Outcome parameters
The primary endpoint was a composite of major adverse car-
diovascular and cerebrovascular events (MACCEs), including 
cardiac death, MI, clinically driven target lesion revasculariza-
tion and stroke. Deaths were classified as cardiac or non-car-
diac, and death of any unidentified cause or in which a cardiac 
cause could not be excluded was classified as cardiac in this 
study. MI was classified as Q wave or non-Q wave, and was de-
fined as a rise in creatine kinase enzyme concentrations above 
twice the normal upper limit. Re-interventions inside the im-
planted stent or within 5 mm proximal or distal to the stent 
were classified as target lesion revascularization (TLR). The 
definition of TLR had been registered according to the SIRIUS 
criteria. That is, TLR is defined as any “clinically-driven” repeat 
percutaneous intervention of the target lesion or bypass sur-
gery of the target vessel. Clinically-driven revascularizations are 
those in which the patient has a positive functional study, isch-
emic electrocardiographic changes at rest in a distribution con-
sistent with the target vessel, or ischemic symptoms, and an 
in-lesion diameter stenosis ≥50% by QCA. Revascularization 
of a target lesion with an in-lesion diameter stenosis ≥70% (by 
QCA) in the absence of the above-mentioned ischemic signs or 
symptoms was also considered clinically driven. In the absence 
of QCA data for relevant follow-up angiograms, clinical need for 
revascularization was adjudicated using the presence or ab-
sence of ischemic signs and symptoms. Repeated PCI to the 
same vessel with the exception of TLR was counted as non-
target lesion (TL) target vessel revascularization (TVR). Target 
vessel failure was defined as all target vessel-related events, 
which included cardiac death, MI, thrombosis, and TVR. Ac-
cording to the Academic Research Consortium Classification, 
definite and probable stent thrombosis was considered stent 
thrombosis.11
Statistical analysis
Statistical analysis was performed using SPSS (version 18.0.0, 
SPSS Inc., Chicago, IL, USA) and R (version 2.8.0, R Foundation 
for Statistical Computing, Vienna, Austria). Continuous vari-
ables are presented as mean ±standard deviation and were 
compared using a Student unpaired t-test. Categorical variables 
are presented as counts and percentages, and were compared 
using chi-square test. Control of confounders between both 
registries was undertaken by propensity score matching (PSM). 
The propensity score is the probability of treatment assignment 
conditional on observed baseline characteristics. The propen-
sity score allows one to design and analyze an observational 
(nonrandomized) study, so that it mimics some of the particu-
lar characteristics of a randomized controlled trial.12
Propensity scores were estimated by fitting a logistic regres-
sion model using the following variables for Nobori and Reso-
lute stents: age over 65 years old, gender, diabetes mellitus, prior 
history of MI, PCI, and coronary artery bypass graft (CABG), 
clinical presentation of acute coronary syndrome, and angio-
graphic coronary artery disease findings. Propensity scores 
yielded a C statistic of 0.635, indicating a good ability to differen-
tiate between two groups of patients. Nearest neighbor match-
ing with a caliper of 0.001 was used. The Hansen and Bowers 
balance test p value was 1.000, indicating good covariate bal-
ance. Table 1 shows a list of variables used to construct the pro-
pensity score. If a subject of the NOBORI group could not be 
matched to any subject of the CONSTANT group, that subject 
was discarded from the matched analysis. Finally, of 2083 pa-
tients in both groups, 1398 patients (67%) were matched. Finally, 
the baseline covariates were compared between the two groups 
with statistical tests for matched data. All p values are 2-sided, 
and p values <0.05 were considered to indicate statistical signifi-
cance.
RESULTS
Characteristics of the study group
Studied patients were derived from our Nobori and CON-
STANT Korea registries. In brief, 1225 patients were undergoing 
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PCI with BES and 858 patients with ZES. The two groups dif-
fered significantly in terms of some potential confounders (Ta-
ble 1). Particularly, patients who received BES were more likely 
to present with diabetes and to be managed as acute coronary 
syndromes. On the other hand, those who received ZES were 
more likely insulin-dependent diabetes and had previous his-
tory of MI. In coronary intervention, Nobori group had more 
left main and left anterior descending coronary artery involve-
ment, and their lesions were more severely calcific, tortuous 
and thrombus with a need for more than one stent in compari-
son with Resolute group. The use of intravascular ultrasound 
evaluation IVUS and bifurcation side-branch stenting was high-
er in Nobori group, while multivessel involvement was higher 
in the Resolute group.
The two groups did not differ significantly in terms of age, 
gender, hypertension, hyperlipidemia, past history of coronary 
bypass surgery, previous percutaneous interventions, and his-
tory of cerebrovascular accidents. Nobori group had higher 
tendency to present with hyperlipidemia. After PSM (Table 2) 
was performed for the entire group (n=2083), there were 699 
matched pairs of patients. In matched analysis, two propensity-
matched groups (699 pairs, n=1398 patients) were generated 
and the baseline characteristics of these two groups were bal-
anced. In this matched cohort, the mean age was 64.5 years, 
men accounted for 72.7%, 32.9% were diabetes mellitus, 61.2% 
were hypertensive, and 45.9% were hyperlipidemic. Clinically, 
52.9% presented with acute coronary syndromes. 22.3% had a 
multivessel disease, 6.7% had severely calcific lesions, 8.7% of 
lesions were thrombus containing and 11.8% were bifurcated 
lesions. The mean total stent length was 22.4 mm and mean 
minimal stent diameter was 22.3 mm. In matched group, there 
was no significant difference between the Nobori and Reso-
lute group in any other covariates.
Table 1. Baseline Characteristics of both Groups (before Matching)
Variables BES (n=1225) ZES (n=858) p value
Age, yrs 64.2±11.1 64.6±11.4 0.224
Male 872 (71.2) 609 (71) 0.922
Hypertension 735 (60) 534 (62.2) 0.268
Diabetes mellitus 377 (30.8) 307 (35.8) 0.01*
Dyslipidemia 525 (42.9) 394 (45.9) 0.09
Current smoker 561 (45.8) 372 (43.4) 0.145
Previous MI 60 (4.9) 68 (7.9) 0.003†
Previous PCI 255 (20.8) 202 (23.5) 0.077
Previous CABG 30 (2.4) 15 (1.7) 0.177
Previous valve surgery 11 (0.9) 4 (0.5) 0.190
Previous CVA 118 (9.6) 89 (10.4) 0.314
Family history of CAD 48 (3.9) 22 (2.6) 0.06
ACS (UA, MI) 659 (53.8) 417 (48.6) 0.01*
Multi vessel disease 210 (17.1) 257 (30) <0.001†
Target lesion  0.012*
LM 38 (3.1) 40 (4.7)
LM-LAD 613 (50) 376 (43.8)
RCA 355 (29) 289 (33.7)
LCX-ramus 219 (17.9) 153 (17.8)
LM involvement 651 (53.1) 416 (48.5) 0.037*
Total stent length, mm 22.24±10.79 22.84±7.82 0.165
Severe calcification 83 (6.8) 52 (6.1) <0.001†
>90% tortuosity 41 (3.3) 28 (3.3) <0.001†
Thrombus containing 117 (9.6) 60 (7) 0.046*
Side branch stenting 5 (0.4) 0 (0) 0.082
BES, Biolimus-eluting stent; ZES, Zotarolimus-eluting stent; ACS, acute coro-
nary syndrome; UA, unstable angina; MI, myocardial infarction; CABG, coro-
nary artery bypass graft; CAD, coronary artery disease; PCI, percutaneous 
coronary intervention; CVA, cerebrovascular accidents; LM, left main; LAD, 
left anterior descending; RCA, right coronary artery; LCX, left circumflex.
Values are mean±SD or n (%). p values are from t-test for continuous vari-
ables and chi-square for binary variables.
*Significant, †Highly significant.
Table 2. Baseline Characteristics of both Groups (after Matching)
Variable BES (n=699) ZES (n=699) p value
Age, yrs 64.9±10.8 64.5±11.6 0.479
≥65 yr-old 380 (54.4) 382 (54.6) 0.914
Male 508 (72.7) 508 (72.7) 1.000
Hypertension 271 (38.8) 271 (38.8) 1.000
Diabetes mellitus 231 (33.0) 229 (32.8) 0.909
Dyslipidemia 306 (43.8) 335 (47.9) 0.120
Current smoker 316 (45.2) 312 (44.6) 0.830
Previous myocardial infarction 21 (3.0) 23 (3.3) 0.759
Previous PCI 122 (17.5) 124 (17.7) 0.888
Previous CABG 5 (0.7) 5 (0.7) 1.000
Acute coronary syndrome 369 (52.8) 371 (53.1) 0.915
Previous CVA 118 (9.6) 89 (10.4) 0.603
FH of CAD 48 (3.9) 22 (2.6) 0.108
CAD 1.000
One vessel 295 (42.2) 295 (42.2)
Two vessel 248 (35.5) 248 (35.5)
Three vessel 156 (22.3) 156 (22.3)
Target lesion 0.932
LM 13 (1.9) 15 (2.1)
LM-LAD 347 (49.6) 352 (50.4)
RCA 212 (30.3) 213 (30.5)
LCX-ramus 119 (17) 127 (18.2)
LM involvement 360 (51.5) 367 (52.5) 0.748
Total stent length, mm 22.24±10.79 22.84±7.22 0.154
Severe calcification 52 (7.4) 41 (5.9) 0.283
>90% tortuosity 29 (4.1) 23 (3.3) 0.48
Thrombus containing 62 (8.9) 59 (8.4) 0.849
Side branch stenting 5 (0.4) 0 (0) 0.082
BES, Biolimus-eluting stent; ZES, Zotarolimus-eluting stent; CABG, coronary 
artery bypass graft; CAD, coronary artery disease; PCI, percutaneous coro-
nary intervention; CVA, cerebrovascular accidents; LM, left main; LAD, left 
anterior descending; RCA, right coronary artery; LCX, left circumflex.
Values are mean±SD or n (%).
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1-year clinical outcomes of the matched cohorts
Table 3 shows 12-months clinical outcomes after PSM. Among 
MACCEs components, there was no significant difference be-
tween Nobori and Resolute groups in terms of either target le-
sion revascularization (1.1% Nobori vs. 0.7% Resolute, p=0.579) 
or TVR [5 cases in either group (0.72%)]. Cardiac death was also 
similar, occurring in 0.7% in patients who received Nobori vs. 
0.4% in those received Resolute (p=0.73), as was non-Q wave 
MI, 0.14% in both groups. There was neither Q wave MI nor 
stent thrombosis in the matched cohorts. Hemorrhagic stroke 
occurred once in the Nobori group 0.1%, and bleeding was also 
similar; four cases (0.6%) in either group. Non-TVR was simi-
lar between Nobori and Resolute [11% vs. 10%, respectively 
(p=1.000)].
DISCUSSION
The main findings of this observational study with 2083 pa-
tients, comparing the safety and efficacy profile of second-gen-
eration Resolute Integrity durable polymer ZES with Nobori 
biodegradable polymer BES, can be summarized as follows. 
First, patients who received BES in the NOBORI registry had 
very different characteristics from those who were implanted 
with ZES in CONSTANT registry. They were presented with 
more coronary risk factors and comorbidities, were more likely 
to be treated in the context of acute coronary syndromes, had 
more left main- left anterior descending artery involvement 
had more severe, calcific, thrombus containing lesions. Second, 
after accounting for these multiple confounders by PSM, there 
were no differences between BES and ZES at 1 year in terms 
of a composite endpoint of cardiovascular death, target vessel 
MI, and clinically driven target lesion revascularization. These 
findings suggest a different degree of patients and lesion subset 
selection in daily use of the third generation Nobori BES, trans-
lating into 12- month outcomes that resemble those of matched 
second-generation Resolute integrity ZES. Excellent outcomes 
were seen for both stent types regarding stent thrombosis. 
This is important in view of disease complexity, including a 
high frequency of acute coronary syndromes.
Our event rates for the primary endpoints in patients who 
received the durable polymer ZES were consistent with previous 
trials.13 A randomized controlled Scandinavian Organization 
for Randomized Trials with Clinical Outcome (SORT-OUT VI) 
showed that durable polymer Resolute Integrity stent (Medtron-
ic, Santa Rosa, CA, USA) was not inferior to the biodegradable 
polymer Biolimus stent (Terumo Corporation, Tokyo, Japan), 
since there were no significant differences in the individual co-
mponents of the primary endpoint (cardiac death, target-ves-
sel-related MI, and clinically indicated TVR). Although similar 
in non-significance, our event rates were lower (composite pri-
mary end point was 2.6% vs. 5.3% in Nobori BES group, 1.7% 
vs. 5% in Resolute integrity ZES group, respectively).
In DUTCH PEERS trial, ZES (Medtronic) was studied against 
the durable polymer Everolimus-eluting Promus Element stent 
(Boston Scientific, Natick, MA, USA), and no significant differ-
ences were found in cardiac death, target vessel related MI or 
clinically indicated TVR; The stent thrombosis rate at 12 months 
was low: 0.3% for the ZES and 0.7% for the Everolimus-eluting 
stent.14 The lower rate of stent thrombosis in Resolute Integrity 
ZES was consistent with our findings.
Final 5-year report of RESOLUTE All-Comers trial showed 
that the Resolute durable-polymer ZES was not inferior to the 
Xience durable polymer Everolimus-eluting stent (Abbott Vas-
cular, Abbott Park, IL, USA) with regard to the primary endpoint 
defined as a composite of cardiac death, MI or clinically driven 
target-lesion revascularization at 12 months.15 The event rate for 
the primary endpoint for the Resolute stent was 8.2% and stent 
thrombosis rate was 4.2%. This is much higher than our rate for 
Resolute ZES and might be attributable to their higher non-Q 
wave MI rate.
The Resolute Integrity is a 91-μm strut made from a single 
strand of cobalt chromium alloy designed in a continuous sinu-
soid technology to optimize deliverability and radial strength.16 
The low rates of stent thrombosis might be due to its thin strut 
thickness and the altered dynamics of drug release which is 
slow in comparison to its first generation counterpart which 
had a rapid drug release and hence a reported higher rate of 
stent thrombosis.17,18
Many methods were evaluated with the aim of removing 
polymers from stent design, because of potential hazard of late 
stent thrombosis. The newer metal alloys with increased st-
rength have allowed for abluminal scoring without affecting 
overall stent strength.19 The biodegradable polymer in Biolimus 
eluting stent consists of polylactic acid (PLA), applied to the 
abluminal surface of the stent and is fully degraded into car-
bon dioxide and water within 6 months. The Nobori BES stent 
Table 3. MACCEs at One-Year Follow-Up Period
Variables BES (n=699) ZES (n=699) p value
Target lesion revascularization 8 (1.1) 5 (0.7) 0.579
Target vessel revascularization 5 (0.72) 5 (0.72) NS
Non-Q myocardial infarction 1 (0.14) 1 (0.14) NS
Q wave myocardial infarction 0 (0) 0 (0) NS
Stent thrombosis 0 (0) 0 (0) NS
All cause death 7 (1) 4 (0.6) 0.55
Cardiac death 5 (0.7) 3 (0.4) 0.73
CVA 1 (0.1) 0 (0) NS
Ischemic stroke 0 (0) 0 (0) NS
Hemorrhagic stroke 1 (0.14) 0 (0) NS
Bleeding 4 (0.6) 4 (0.6) NS
MACCEs 18 (2.6) 12 (1.7) 0.36
NS, non-significant; BES, Biolimus-eluting stent; ZES, Zotarolimus-eluting 
stent; CVA, cerebrovascular accidents; MACCEs, major adverse cardiovascu-
lar and cerebrovascular events.
Values are mean±SD or n (%).
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(Terumo Corporation, Tokyo, Japan) uses 316L stainless steel 
and abluminal PLA polymer.20
Patients with biodegradable polymer stents had fewer TVR 
and stent thrombosis than those treated with first-generation 
DES.21 This new design was expected to be better in terms of 
safety and efficacy compared to durable polymer one. How-
ever, subsequent studies showed somewhat different findings, 
which is consistent with our present results.
The Nobori biodegradable-polymer stent (Terumo, Tokyo, Ja-
pan) was not inferior to the Xience stent with durable polymer 
coating in the COMPARE II trial.22
LEADERS trial23 showed that compared with Cypher Sirolim-
us durable eluting stent SES (Cordis, Miami Lakes, FL, USA), 
the Biomatrix Biolimus biodegradable eluting stent was not in-
ferior in safety at 9 months. However, in their follow-up report 
beyond the first year, they reported that the risk of MACE was 
lower in patients treated with BES than in those treated with 
SES (18.7% vs. 22.6%; p=0.050). The relative risk of definite stent 
thrombosis ST was 0.62 (p=0.09), which was largely attributed 
to a lower risk of very late definite ST between years 1 and 4 in 
the BES compared to the SES group (RR 0.20, p=0.004), demon-
strating 80% relative risk reduction. 
Similarly, BES did not fare well enough to be declared non-
inferior versus a cypher Sirolimus-eluting standard-polymer 
stent with respect to a combined 9 month safety/efficacy end-
point in a randomized trial of patients with chronic stable angi-
na,13 indicating that evolving durable polymers might be at least 
as efficacious as biodegradable polymers.
The two stents in our study have different characteristics. The 
Nobori BES platform is composed of stainless steel with a strut 
thickness of 112 μm. It is coated with a PLA polymer on its ablu-
minal surface, which is metabolized within 6–9 months to lactic 
acid, water, and carbon dioxide. The stent elutes an antiprolif-
erative drug, Biolimus (15.6 μg/mm), for up to 30 days. The 
coating design as well as the lipophilicity of the drug is thought 
to optimize local drug distribution and to reduce its release into 
circulation. At the end, the Nobori stent will leave only a bare 
metal stent BMS in place.24 On the other hand, Resolute Integ-
rity is made of cobalt-chromium alloy with a lesser strut thick-
ness of 91 μm, and the 5.6-μm-thick BioLinx multi-polymeric 
system, which covers the entire stent platform, elutes Zotaroli-
mus as the antiproliferative agent in a controlled manner.25
Some previous studies suggested that the stent strut thick-
ness and design are responsible for DES safety profile irre-
spective of the drug coating.26 In our present study, we found no 
difference between the two stent types in spite of the differ-
ence in strut thickness and design. Therefore, we are not cer-
tain whether the stent design and strut thickness affect safety 
and efficacy. This is consistent with the findings of BIOSCI-
ENCE randomized controlled trial, stating that an ultrathin strut 
biodegradable polymer Sirolimus-eluting stent at 12 months 
was non-inferior to a durable polymer Everolimus-eluting stent 
for percutaneous coronary revascularization.27
Further studies are needed to clarify this concept. Although a 
large number of patients in our study experienced fewer events, 
particularly MIs, and stent thrombosis, this might be due to a 
short follow-up duration of 12 months. Therefore, more time is 
needed to assess the risk of late stent thrombosis and the inci-
dence of MIs.
The rate of major adverse cardiac and cerebrovascular events 
was lower in the Resolute ZES than those in Nobori BES. This 
might be due to higher risk patients in Nobori BES group and 
the more difficult coronary lesions subsets. Furthermore, the 
results for our endpoints might be limited by the short follow-
up period. 
In conclusion, in this large cohort of patients undergoing 
PCI with Nobori BES or Resolute Integrity ZES, we found that 
the rate of major cardiac and cerebrovascular adverse events at 
1 year was low, and that the difference different between both 
groups was statistically insignificant.
Limitations
We have some limitations about this article. First, this article is 
not a randomized controlled clinical trial; therefore, our com-
parison between new generation stents even after propensity 
matching to overcome the limitation should be carefully ana-
lyzed and applied individually for real world practice. Second, 
intravascular imaging tools such as intravascular ultrasound, 
and optical coherence tomography can unravel strong clue for 
final discrimination about information of neointimal coverage 
and failure of apposition between different designs and charac-
ter of stents. However, because of limitation of registry data, we 
are not able to suggest about parameters for vascular imaging.
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